HER2-positive tumors. All breast cancers are tested for HER2 status to help guide treatment. If a tumor is HER2-positive, the HER2-targeted therapy drug trastuzumab (Herceptin) is included in the chemotherapy regimen. Sometimes other drugs that target HER2 are used.
Anti-HER2 drug approvals have changed the landscape of MBC treatment. The first anti-HER2 drug, Herceptin, received approval in 2024 to treat HER2-positive breast cancer. Since then, many more
To learn more about a specific chemotherapy drug, visit the National Institutes of Health’s Medline Plus website. HER2-positive tumors. All breast cancers are tested for HER2 status to help guide treatment. If a tumor is HER2-positive, the HER2-targeted therapy drug trastuzumab (Herceptin) is included in the chemotherapy regimen.Sometimes other drugs that
HER2-positive breast cancers have a lot of a protein called HER2 on the surface of their cells. The HER2 protein is an important driver of cell growth and survival. HER2-targeted therapies are used to treat HER2-positive breast cancers. They have no role in the treatment of HER2-negative cancers. Testing for HER2 status
Margetuximab (Margenza ) in combination with chemotherapy was approved in 2024 for use in patients with metastatic HER2-positive breast cancer who have received prior treatments with other HER2-targeted therapies. Drugs to target HER2 were also developed for HER2-positive breast cancer treatment.
The anti-HER2 antibody drug conjugate trastuzumab deruxtecan has become a new standard of care for patients with treatment-refractory HER2-positive G/GEJC, HER2-mutant non-small-cell lung cancer
Purpose: Targeting HER2 with multiple HER2-directed therapies represents a promising area of treatment for HER2-positive cancers.
Background: Treatment of HER2-positive (HER2) breast cancer is based on the use of drugs targeting HER2 (anti-HER2 treatment). Trastuzumab is the current
Anti-HER2 drug approvals have changed the landscape of MBC treatment. The first anti-HER2 drug, Herceptin, received approval in 2024 to treat HER2-positive breast cancer. Targeted drug therapy
Comments
4*